Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
2Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Former Chairman and CEO of Madrigal (retired September 2023). Former CEO of Incyte (2001-2014). Extensive R&D leadership experience at DuPont and Merck. Associate Professor at Harvard Medical School. Non-executive Chairman of Prelude Therapeutics.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Prelude Therapeutics Inc

2016-01-01 · current

Confirmed by public sourceView source

Director

MADRIGAL PHARMACEUTICALS, INC.

2016-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

MADRIGAL PHARMACEUTICALS, INC.

Open MADRIGAL PHARMACEUTICALS, INC. profile →

Director at MADRIGAL PHARMACEUTICALS, INC.

2016-01-01 → End not stated

current · source reported

Observed: 2026-09-21

MADRIGAL PHARMACEU…MADRIGAL PHARMACEUTICALS, INC.Prelude Therapeuti…Prelude Therapeutics IncPaul A. Friedman, …

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingMDGL DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingPRLD DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:paul-a-friedman-m-d
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · Source reportedNot independent (executive director)1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · CorroboratedServes on the board of Madrigal PharmaceuticalsSupported by 3 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board membership · CorroboratedServes on the board of Prelude Therapeutics IncSupported by 2 public records2 sources
Verification
Corroborated
Confidence
95%
Last reviewed
May 3, 2026
Board role · Source reportedBoard role: Chair1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Science/Innovation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources7 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Director since · Board independence

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  4. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Sec Proxy · Tier not stated · Reviewed May 1, 2026

    Supports: Director at MADRIGAL PHARMACEUTICALS, INC. (NASDAQ: MDGL)

  5. https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Prelude Therapeutics Inc (NASDAQ: PRLD)

  6. https://www.sec.gov/Archives/edgar/data/1678660/000095017025059549/prld-20250429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  7. https://www.sec.gov/Archives/edgar/data/1157601/000110465925041254/tm2512589-3_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership